19:52 , Oct 13, 2017 |  BC Week In Review  |  Company News

AbbVie acquires options to Turnstone immunotherapies

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad-MG1-MAGEA3. By combining oncolytic viruses with cancer vaccines, Turnstone aims to develop...
22:18 , Oct 10, 2017 |  BC Extra  |  Company News

AbbVie, Turnstone in oncolytic virus deal

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad-MG1-MAGEA3. By combining oncolytic viruses with cancer vaccines, Turnstone aims to develop...
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
20:05 , May 19, 2017 |  BC Week In Review  |  Clinical News

Turnstone begins Phase I/II NSCLC trial of viral therapy

Turnstone Biologics Inc. (Ottawa, Ontario) began the Phase I/II Sandpiper trial of its adenovirus expressing melanoma-associated antigen A3 (MAGEA3)/MG1 Maraba virus expressing MAGEA3 (MG1-MAGEA3) plus Keytruda pembrolizumab to treat metastatic non-small cell lung cancer (NSCLC)...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Adenovirus expressing melanoma-associated antigen A3: Phase I/IIa started

Turnstone began an open-label, dose-escalation, Canadian Phase I/IIa trial to compare adenovirus expressing MAGEA3/MG1 Maraba virus expressing MAGEA3 vs. the product’s 2 components separately in up to 79 patients. The priming component of the product...